MYC, FBXW7 and TP53 copy number variation and expression in Gastric Cancer

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Calcagno, Danielle Q ^a,b   Freitas, Vanessa M ^c   Leal, Mariana F ^b   de Souza, Carolina R T ^a   Demachki, Samia ^a   Montenegro, Raquel ^a   Assumpção, Paulo P ^a   Khayat, André S ^a   Smith, Marília D A C ^b   dos Santos, Andrea K C R ^a   Burbano, Rommel R ^a  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

FBXW7; Gastric cancer; MYC; TP53

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; MYC PROTEIN; PROTEIN FBXW7; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; ENZYME ACTIVITY; ENZYME SYNTHESIS; FBXW7 GENE; FEMALE; GENE; GENE AMPLIFICATION; GENE DELETION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PHENOTYPE; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA; STOMACH CANCER; STROMA CELL; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ADULT; AGED; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DNA COPY NUMBER VARIATIONS; F-BOX PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84884400805     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-141     Document Type: Article

References (49)

1. Brenner H, Rothenbacher D, Arndt V. Epidemiology of stomach cancer. Methods in molecular biology (Clifton, NJ 2009, 472:467-477.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241(1):27-39. 1356843, 15621988.
3. Smith MG, Hold GL, Tahara E, El-Omar EM. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 2006, 12(19):2979-2990.
4. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006, 16(4):253-264. 10.1016/j.semcancer.2006.07.014, 16904903.
5. Calcagno DQ, Leal MF, Assumpcao PP, Smith MA, Burbano RR. MYC and gastric adenocarcinoma carcinogenesis. World J Gastroenterol 2008, 14(39):5962-5968. 10.3748/wjg.14.5962, 2760197, 18932273.
6. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem 2006, 281(46):34725-34729. 10.1074/jbc.R600017200, 16987807.
7. Bashir T, Pagano M. Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis. Adv Cancer Res 2003, 88:101-144.
8. Nakayama KI, Nakayama K. Regulation of the cell cycle by SCF-type ubiquitin ligases. Seminars in cell & developmental biology 2005, 16(3):323-333. 10.1016/j.semcdb.2005.02.010, 23811289.
9. Onoyama I, Nakayama KI. Fbxw7 in cell cycle exit and stem cell maintenance: insight from gene-targeted mice. Cell cycle (Georgetown, Tex 2008, 7(21):3307-3313.
10. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004, 432(7018):775-779. 10.1038/nature03155, 15592418.
11. Welcker M, Clurman BE. Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell division 2007, 2:7. 10.1186/1747-1028-2-7, 1802738, 17298674.
12. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67(19):9006-9012. 10.1158/0008-5472.CAN-07-1320, 17909001.
13. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuwano H, Nakayama KI, Mori M. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 2009, 69(9):3788-3794. 10.1158/0008-5472.CAN-08-2846, 19366810.
14. Kountouras J, Zavos C, Chatzopoulos D. New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 2005, 52(64):1305-1312.
15. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So- Called Intestinal-Type Carcinoma. an Attempt at a Histo-Clinical Classification. Acta pathologica et microbiologica Scandinavica 1965, 64:31-49.
16. Clayton CL, Kleanthous H, Morgan DD, Puckey L, Tabaqchali S. Rapid fingerprinting of Helicobacter pylori by polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol 1993, 31:1420-1425. 265554, 8100240.
17. Covacci A, Falkow S, Berg DE, Rappuoli R. Did the inheritance of a pathogenicity island modify the virulence of Helicobacter pylori?. Trends Microbiol 1997, 5:205-208. 10.1016/S0966-842X(97)01035-4, 9160510.
18. Leal MF, Martins do Nascimento JL, da Silva CE, Vita Lamarao MF, Calcagno DQ, Khayat AS, Assumpcao PP, Cabral IR, de Arruda Cardoso Smith M, Burbano RR. Establishment and conventional cytogenetic characterization of three gastric cancer cell lines. Cancer Genet Cytogenet 2009, 195(1):85-91. 10.1016/j.cancergencyto.2009.04.020, 19837275.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-timequantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
20. Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985, 318:533-538. 10.1038/318533a0, 3906410.
21. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P. Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell 1986, 45:485-495. 10.1016/0092-8674(86)90280-1, 3011271.
22. Calcagno DQ, Leal MF, Taken SS, Assumpcao PP, Demachki S, Smith Mde A, Burbano RR. Aneuploidy of chromosome 8 and C-MYC amplification in individuals from northern Brazil with gastric adenocarcinoma. Anticancer Res 2005, 25(6B):4069-4074.
23. Calcagno DQ, Leal MF, Seabra AD, Khayat AS, Chen ES, Demachki S, Assumpcao PP, Faria MH, Rabenhorst SH, Ferreira MV, et al. Interrelationship between chromosome 8 aneuploidy, C-MYC amplification and increased expression in individuals from northern Brazil with gastric adenocarcinoma. World J Gastroenterol 2006, 12(38):6207-6211.
24. Burbano RR, Assumpcao PP, Leal MF, Calcagno DQ, Guimaraes AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M. C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res 2006, 26(4B):2909-2914.
25. Costa Raiol LC, Figueira Silva EC, Mendes da Fonseca D, Leal MF, Guimaraes AC, Calcagno DQ, Khayat AS, Assumpcao PP, de Arruda Cardoso Smith M, Burbano RR. Interrelationship between MYC gene numerical aberrations and protein expression in individuals from northern Brazil with early gastric adenocarcinoma. Cancer Genet Cytogenet 2008, 181(1):31-35. 10.1016/j.cancergencyto.2007.10.011, 18262050.
26. Calcagno DQ, Guimaraes AC, Leal MF, Seabra AD, Khayat AS, Pontes TB, Assumpcao PP, De Arruda Cardoso Smith M, Burbano RR. MYC insertions in diffuse-type gastric adenocarcinoma. Anticancer Res 2009, 29(7):2479-2483.
27. Leal MF, Calcagno DQ, Borges da Costa Jde F, Silva TC, Khayat AS, Chen ES, Assumpção PP, de Arruda Cardoso Smith M, Burbano RR. MYC, TP53, and chromosome 17 copy-number alterations in multiple gastric cancer cell lines and in their parental primary tumors. J Biomed Biotechnol 2011, 2011:631268. 3082130, 21528007.
28. Park KU, Lee HE, Park do J, Jung EJ, Song J, Kim HH, Choe G, Kim WH, Lee HS. MYC quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med 2009, 47(5):530-536.
29. Eick D, Piechaczyk M, Henglein B, Blanchard JM, Traub B, Kofler E, Wiest S, Lenoir GM, Bornkamm GW. Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer half-lives. EMBO J 1985, 4(13B):3717-3725. 554723, 3004968.
30. Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis 2005, 26(12):2031-2045. 10.1093/carcin/bgi223, 16150895.
31. Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H, Okanoue T, Inazawa J. Screening of DNA copy-number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer science 2005, 96(2):100-110. 10.1111/j.1349-7006.2005.00016.x, 15723654.
32. Panani AD. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer letters 2008, 266(2):99-115. 10.1016/j.canlet.2008.02.053, 18381231.
33. Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004, 431(7012):1112-1117. 10.1038/nature03043, 15475948.
34. Yu D, Dews M, Park A, Tobias JW, Thomas-Tikhonenko A. Inactivation of Myc in murine two-hit B lymphomas causes dormancy with elevated levels of interleukin 10 receptor and CD20: implications for adjuvant therapies. Cancer Res 2005, 65(12):5454-5461. 10.1158/0008-5472.CAN-04-4197, 1490323, 15958595.
35. Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res 2005, 65(11):4471-4474. 10.1158/0008-5472.CAN-05-1172, 15930260.
36. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. Modelling Myc inhibition as a cancer therapy. Nature 2008, 455:679-683. 10.1038/nature07260, 18716624.
37. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes & development 1998, 12:2424-2433. 10.1101/gad.12.15.2424, 3783832, 24093083.
38. Pelengaris S, Khan M. The many faces of c-MYC. Arch Biochem Biophys 2003, 416:129-136. 10.1016/S0003-9861(03)00294-7, 12893289.
39. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993, 329(18):1318-1327. 10.1056/NEJM199310283291807, 8413413.
40. Chang F, Syrjanen S, Syrjanen K. Implications of the p53 tumor-suppressor gene in clinical oncology. J Clin Oncol 1995, 13(4):1009-1022.
41. Renault B, van den Broek M, Fodde R, Wijnen J, Pellegata NS, Amadori D, Khan PM, Ranzani GN. Base transitions are the most frequent genetic changes at P53 in gastric cancer. Cancer Res 1993, 53(11):2614-2617.
42. Seruca R, David L, Castedo S, Veiga I, Borresen AL, Sobrinho-Simoes M. p53 alterations in gastric carcinoma: a study of 56 primary tumors and 204 nodal metastases. Cancer Genet Cytogenet 1994, 75(1):45-50. 10.1016/0165-4608(94)90214-3, 8039163.
43. Poremba C, Yandell DW, Mellin W, Schmid KW, Reers B, Bocker W, Dockhorn-Dworniczak B. Adenocarcinoma of the cardia in a young man: detection of somatic p53 mutation by immunohistochemistry and automated direct sequencing. Pathol Res Pract 1995, 191(10):1004-1009. 10.1016/S0344-0338(11)80599-6, 8838368.
44. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253:49-53. 10.1126/science.1905840, 1905840.
45. Khayat AS, Guimaraes AC, Calcagno DQ, Seabra AD, Lima EM, Leal MF, Faria MH, Rabenhorst SH, Assumpcao PP, Demachki S, et al. Interrelationship between TP53 gene deletion, protein expression and chromosome 17 aneusomy in gastric adenocarcinoma. BMC gastroenterology 2009, 9:55. 10.1186/1471-230X-9-55, 2716360, 19619279.
46. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010, 14(1):52-67.
47. Kong L, Sun JW, Zhang CH. The expression of integrinalphanubeta6 and MMP-9 in gastric cancer and the correlation with clinicopathologic characteristic. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2011, 27(1):92-94.
48. Kubben FJ, et al. Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. Br J Cancer 2006, 94(7):1035-1040. 10.1038/sj.bjc.6603041, 2361233, 16538217.
49. Sampieri CL, et al. Expression of matrix metalloproteinases 2 and 9 in human gastric cancer and superficial gastritis. World J Gastroenterol 2010, 16(12):1500-1505. 10.3748/wjg.v16.i12.1500, 2846256, 20333791.